Here's Why Mirati Therapeutics Jumped 28% in December
Results from a combination study breathed life into the company's sitravatinib program.
Mirati Therapeutics
MRTX
MRTX
$161.09
-$0.88
-0.5%
Price as of September 18, 2020, 4:30 p.m. EDT
View Interactive MRTX Charts
Mirati Therapeutics, Inc.
Interactive Chart
News & Analysis: Mirati Therapeutics
3 Cancer Treatment Stocks to Buy Right Now
MIrati Therapeutics, Iovance Biotherapeutics, and Personalis are all using genetic knowledge to help find cures for cancer.
Better Buy: Mirati Therapeutics vs. Amgen
Both biotechs are developing revolutionary new cancer drugs, but which stock is better for your portfolio right now?
Can This Tiny Biotech Take Down Amgen?
It’s looking competitive in one cancer drug class.
Here's Why Mirati Therapeutics Stock Is on the Move Again Today
This time, its own clinical trial is pushing the biotech higher.
Is Mirati Therapeutics a Good Stock to Buy Now?
This stock could soar at the end of the month, but is it worth the risk?
3 Companies To Watch For At November’s Society for Immunotherapy of Cancer Meeting
Due to the explosion in immuno-oncology in recent years, what was once a small scientific meeting near the end of the year has become a go-to event for drug developers.
Winners and Losers of Europe’s Big Cancer Meeting
Unfortunately, there were more of the latter.
4 Biotech Stocks With Big Catalysts in September
Two presentations at the World Conference on Lung Cancer will make a big difference for at least four different drugmakers.
3 Top Biotech Stocks to Buy Right Now
These three biotech stocks should be outstanding long-term growth vehicles.
